Cheetah Medical launches new hemodynamic monitoring product in Europe

In addition to core hemodynamic parameters including cardiac output, cardiac index and stroke volume, the Reliant 2.0 adds new parameters to provide a comprehensive suite of information for hemodynamic monitoring – all without the need for invasive modalities with the associated potential costs and risks, the company said.

The new parameters include noninvasive blood pressure, total peripheral resistance, stroke volume variation, cardiac power and change in thoracic fluid content.

According to the company, the Reliant hemodynamic monitoring platform is powered by Cheetah’s patented Bioreactance Technology, which has been used effectively in over 2,000 patients in various clinical settings including medical and surgical intensive care, perioperative care, emergency medicine, heart failure, hemodialysis and exercise testing.

Yoav Avidor, CEO of Cheetah Medical, said: “Accurate continuous hemodynamic monitoring to support real-time decisions on fluids and drugs is today a critical component of diagnosis and treatment in many acute conditions, thanks to substantial improvement in patient outcomes. We believe that the Reliant monitor provides the accurate, noninvasive monitoring solution physicians need in order to implement cutting-edge clinical protocols across a wide array of patients in a cost-effective fashion.”